192 related articles for article (PubMed ID: 24942977)
1. A determination of the current causes of hyperkalaemia and whether they have changed over the past 25 years.
Muschart X; Boulouffe C; Jamart J; Nougon G; Gérard V; de Cannière L; Vanpee D
Acta Clin Belg; 2014 Aug; 69(4):280-4. PubMed ID: 24942977
[TBL] [Abstract][Full Text] [Related]
2. [Risk for hyperkalemia during long-term treatment with angiotensin-converting enzyme inhibitors in insulin-dependent type 2 diabetics in relation to the glomerular filtration rate].
Raml A; Schmekal B; Grafinger P; Biesenbach G
Dtsch Med Wochenschr; 2001 Nov; 126(47):1327-30. PubMed ID: 11719857
[TBL] [Abstract][Full Text] [Related]
3. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
Pitt B; Anker SD; Bushinsky DA; Kitzman DW; Zannad F; Huang IZ;
Eur Heart J; 2011 Apr; 32(7):820-8. PubMed ID: 21208974
[TBL] [Abstract][Full Text] [Related]
5. Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients.
Indermitte J; Burkolter S; Drewe J; Krähenbühl S; Hersberger KE
Drug Saf; 2007; 30(1):71-80. PubMed ID: 17194172
[TBL] [Abstract][Full Text] [Related]
6. Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone.
Cruz CS; Cruz AA; Marcílio de Souza CA
Nephrol Dial Transplant; 2003 Sep; 18(9):1814-9. PubMed ID: 12937229
[TBL] [Abstract][Full Text] [Related]
7. [Hyperkalemias].
Radó J; Haris A
Orv Hetil; 1999 Nov; 140(47):2611-8. PubMed ID: 10613044
[TBL] [Abstract][Full Text] [Related]
8. Spironolactone use and renal toxicity: population based longitudinal analysis.
Wei L; Struthers AD; Fahey T; Watson AD; Macdonald TM
BMJ; 2010 May; 340():c1768. PubMed ID: 20483947
[TBL] [Abstract][Full Text] [Related]
9. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
10. Long-term mortality and trajectory of potassium measurements following an episode of acute severe hyperkalaemia.
Gorriz JL; D'Marco L; Pastor-González A; Molina P; Gonzalez-Rico M; Puchades MJ; Sanchis I; Escudero V; Estañ N; de la Espriella R; Nuñez E; Pallardó L; Núñez J
Nephrol Dial Transplant; 2022 Feb; 37(3):522-530. PubMed ID: 33508124
[TBL] [Abstract][Full Text] [Related]
11. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
Khosla N; Kalaitzidis R; Bakris GL
Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
[TBL] [Abstract][Full Text] [Related]
12. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis.
Maddirala S; Khan A; Vincent A; Lau K
Am J Med Sci; 2008 Oct; 336(4):330-5. PubMed ID: 18854676
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
Surabenjawong U; Thunpiphat N; Chatsiricharoenkul S; Monsomboon A
J Med Assoc Thai; 2013 Aug; 96(8):905-10. PubMed ID: 23991595
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
Tamirisa KP; Aaronson KD; Koelling TM
Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
[TBL] [Abstract][Full Text] [Related]
15. Impact of worsening renal function related to medication in heart failure.
Brunner-La Rocca HP; Knackstedt C; Eurlings L; Rolny V; Krause F; Pfisterer ME; Tobler D; Rickenbacher P; Maeder MT;
Eur J Heart Fail; 2015 Feb; 17(2):159-68. PubMed ID: 25808849
[TBL] [Abstract][Full Text] [Related]
16. [A patient with severe hyperkalaemia -- an emergency after RALES].
Nürnberger J; Daul A; Philipp T
Dtsch Med Wochenschr; 2005 Sep; 130(36):2008-11. PubMed ID: 16143930
[TBL] [Abstract][Full Text] [Related]
17. Hyperkalaemia in the age of aldosterone antagonism.
Chapagain A; Ashman N
QJM; 2012 Nov; 105(11):1049-57. PubMed ID: 22723454
[TBL] [Abstract][Full Text] [Related]
18. Hyperkalaemia and haemodialysis patients: eletrocardiographic changes.
Cobo Sánchez JL; Alconero Camarero AR; Casaus Pérez M; Maza Sota MA; Villa Llamazares C; Hiquera Roldán C; Menezo Viadero R; Alonso Nates R
J Ren Care; 2007; 33(3):124-9. PubMed ID: 19160884
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia.
Kuijvenhoven MA; Haak EA; Gombert-Handoko KB; Crul M
Int J Clin Pharm; 2013 Dec; 35(6):1099-104. PubMed ID: 23974985
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and factors associated with false hyperkalaemia in Asians in primary care: a cross-sectional study (the Unlysed Hyperkalaemia- the Unseen Burden (UHUB) study).
Boo AYY; Koh YLE; Hu PL; Tan NC
BMJ Open; 2020 Sep; 10(9):e033755. PubMed ID: 32963061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
